TPR100 will be a product for the provision of topical pain relief and utilises Futura's DermaSys technology. Futura has developed a highly efficient and proprietary delivery technology, DermaSys, for the absorption of active molecules through the skin. The DermaSys technology was originally developed for use in our topical treatment for erectile dysfunction, MED2002. DermaSys is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
The clinical studies to evaluate drug delivery of TPR100 topical formulations developed by Futura have been extended to complete formulation optimisation. Commercial negotiations with GSK are continuing on a non-exclusive basis*.
* GlaxoSmithKline and Futura Medical had entered into an exclusivity agreement for the negotiation of the global distribution rights for TPR100. Under the terms of the agreement, GlaxoSmithKline agreed to pay Futura an upfront fee of £150,000 to enter a period of exclusive discussions and negotiations which concluded on 31 March 2008.
TPR100 utilises our skin delivery technology
